CBP/p300-IN-3
CBP/p300-IN-3, a p300/CBP histone acetyltransferase inhibitor, Compound 6, is sourced from patent WO 2019049061 A1[1].
Product Specifications
CAS Number
[2299226-01-8]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Histone Acetyltransferase
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/p300-cbp-in-3.html
Purity
98.01
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
O=C(C1=CC=C2C(N=C(C3=CC=C(N(CC)CC)N=C3)N2CC4=NN(CC)C=C4)=C1)NC
Molecular Formula
C24H29N7O
Molecular Weight
431.53
Precautions
H302, H315, H319, H335
References & Citations
[1]Jesus Raul Medina, et al. 5- (1 h-benzo[d]imidazo-2-yl) -pyridin-2-amine and 5- (3h-imidazo[4,5-b]pyridin-6-yl) -pyridin-2-amine derivatives as c-myc and p300/cbp histone acetyltransferase inhibitors for treating cancer. WO2019049061A1.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CBP/p300
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
N 018-50 5x 10 µmol
β- Nicotinic acid adenine dinucleotide phosphate (β-NAADP⁺), sodium salt
Ask
View Details 
